autologous BCMA CAR-T cells

Autologous BCMA CAR-T cells (specifically the TUD-BCMA construct) are an investigational cell-based immunotherapy developed by the Technische Universität Dresden. This therapy utilizes a patient's own T lymphocytes, which are genetically engineered via a lentiviral vector to express a chimeric antigen receptor (CAR) specific for the B-cell maturation antigen (BCMA; TNFRSF17). BCMA is a cell surface receptor highly and selectively expressed on mature B lymphocytes and plasma cells, making it an ideal target for plasma cell dyscrasias. Upon re-infusion, these CAR-T cells recognize BCMA-expressing malignant cells and initiate a cytotoxic response, primarily through the activation of 4-1BB and CD3-zeta signaling domains. The program is currently in clinical development for relapsed or refractory multiple myeloma, and is also being explored for other BCMA-positive B-cell malignancies such as certain forms of diffuse large B-cell lymphoma.

Other names

BCMA-directed CAR-T cellsanti-BCMA CAR-T cellsautologous anti-BCMA CAR-T cells